Sugi Predict

Sugi Predict / Compounds / SCHEMBL633225

SCHEMBL633225

SCHEMBL633225

CC(Br)C(=O)c1cccc(Cl)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC6A2 P23975 5/20 0.59
▸ SLC6A3 Q01959 4/20 0.59
▸ CHRNA1 P02708 2/20 0.59
▸ CHRNG P07510 2/20 0.59
▸ CHRNB1 P11230 2/20 0.59
▸ CHRNB2 P17787 2/20 0.59
▸ CHRNB4 P30926 2/20 0.59
▸ SLC6A4 P31645 2/20 0.59
▸ CHRNA3 P32297 2/20 0.59
▸ CHRNA4 P43681 2/20 0.59
▸ CHRND Q07001 2/20 0.59
▸ ITGA5 P08648 1/20 0.59
▸ CYP2C19 P33261 1/20 0.59
▸ HRH1 P35367 1/20 0.59
▸ CHRNA7 P36544 1/20 0.59
▸ OPRK1 P41145 1/20 0.59
▸ KCNH2 Q12809 1/20 0.59
▸ ALDH1A1 P00352 3/20 0.58
▸ SMN1; SMN2 Q16637 2/20 0.58
▸ BLM P54132 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29848174 1.00 SLC6A2 (0.59) SLC6A2SLC6A3CHRNA1CHRNGCHRNB1
SCHEMBL8020335 0.89 SLC6A2 (0.50) SLC6A2SLC6A3CHRNA1CHRNGCHRNB1
SCHEMBL18184925 0.88 SLC6A2 (0.54) SLC6A2SLC6A3CHRNA1CHRNGCHRNB1
SCHEMBL5256414 0.87 SLC6A2 (0.61) SLC6A2SLC6A3CHRNA1CHRNGCHRNB1
SCHEMBL3362673 0.85 PARP1 (0.57) SLC6A2SLC6A3CHRNA1CHRNGCHRNB1
SCHEMBL8159886 0.85 SLC6A2 (0.63) SLC6A2SLC6A3CHRNA1CHRNGCHRNB1
SCHEMBL5048093 0.84 SLC6A2 (0.46) SLC6A2SLC6A3CHRNA1CHRNGCHRNB1
SCHEMBL10898106 0.83 PARP1 (0.55) SLC6A2SLC6A3CHRNA1CHRNGCHRNB1
SCHEMBL10305470 0.83 SLC6A2 (0.61) SLC6A2SLC6A3CHRNA1CHRNGCHRNB1
SCHEMBL2070613 0.83 SLC6A2 (0.61) SLC6A2SLC6A3CHRNA1CHRNGCHRNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 288 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114874084-B Preparation method of bupropion hydrochloride impurity F 浙江普洛家园药业有限公司 2023-12-19 — — CN claimed
CN-115478079-A Method for preparing bupropion intermediate by continuous flow method 哈尔滨工业大学（深圳） 2022-12-16 — — CN claimed
CN-114874084-A Preparation method of bupropion hydrochloride impurity F 浙江普洛家园药业有限公司 2022-08-09 — — CN claimed
US-7737302-B2 Process for preparing bupropion hydrochloride ZHEJIANG APELOA MEDICAL TECHNOLOGY CO., LTD. (CN) 2010-06-15 — — US claimed
US-20090012328-A1 Process for preparing bupropion hydrochloride Zhejiang Apeloa Jiayuan Pharmaceutical Co., Ltd. (CN) 2009-01-08 — — US claimed
US-20080281096-A1 Resolution Process For Preparing (+)-2S,3S)-2-(3-Chlorophenyl)-3,3,3-Trimethyl-2-Morpholinol HARRIS MICHAEL ANTHONY 2008-11-13 — — US claimed
EP-1689725-A1 RESOLUTION PROCESS FOR PREPARING (+)-(2S, 3S)-2-(3-CHLOROPHENYL)-3,3,3-TRIMETHYL-2-MORPHOLINOL SmithKline Beecham Corporation (US) 2006-08-16 — — EP claimed
WO-2005040141-A1 RESOLUTION PROCESS FOR PREPARING (+)-(2S,3S)-2-(3-CHLOROPHENYL)-3,3,3-TRIMETHYL-2-MORPHOLINOL SMITHKLINE BEECHAM CORPORATION (US) 2005-05-06 — — WO claimed
US-20250011315-A1 ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF PRISM MEDICINES, INC. 2025-01-09 — — US disclosed
US-12030876-B2 Aryl hydrocarbon receptor (AHR) agonists and uses thereof Ikena Oncology, Inc. (US) 2024-07-09 — — US disclosed
US-12030876-B2 Aryl hydrocarbon receptor (AHR) agonists and uses thereof Ikena Oncology, Inc. (US) 2024-07-09 — — US disclosed
US-12030876-B2 Aryl hydrocarbon receptor (AHR) agonists and uses thereof Ikena Oncology, Inc. (US) 2024-07-09 — — US disclosed
CN-114874084-B Preparation method of bupropion hydrochloride impurity F 浙江普洛家园药业有限公司 2023-12-19 — — CN disclosed
CN-114874084-B Preparation method of bupropion hydrochloride impurity F 浙江普洛家园药业有限公司 2023-12-19 — — CN disclosed
EP-0842923-A1 PYRROLE DERIVATIVES AND MEDICINAL COMPOSITION NIPPON SHINYAKU COMPANY, LIMITED (JP) 1998-05-20 — — EP disclosed
US-4690931-A IN TREATMENT OF ANOXIA OR BRAIN DAMAGE SYNTHELABO (FR) 1987-09-01 — — US disclosed
EP-0118036-A1 Biologically active ketone derivative, preparation and use THE WELLCOME FOUNDATION LIMITED (GB) 1984-09-12 — — EP disclosed
EP-0005783-B1 IMIDAZO (2.1-B)-(1.3.4)-THIADIAZOLES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN MEDICAMENTS BAYER AG (DE) 1981-12-30 — — EP disclosed
US-4265898-A ANTICOAGULANTS BAYER AKTIENGESELLSCHAFT (DE) 1981-05-05 — — US disclosed
EP-0005783-A1 Imidazo (2.1-b)-(1.3.4)-thiadiazoles, process for their preparation and their use in medicaments BAYER AG (DE) 1979-12-12 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250011315-A1 ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF AHR, ARNT, HCAR1 SLC6A2 2884/4885SLC6A3 2700/4885CHRNA1 515/4885
US-12030876-B2 Aryl hydrocarbon receptor (AHR) agonists and uses thereof AHR, ARNT, HCAR1 SLC6A2 2884/4885SLC6A3 2700/4885CHRNA1 515/4885
US-20080281096-A1 Resolution Process For Preparing (+)-2S,3S)-2-(3-Chlorophenyl)-3,3,3-Trimethyl-2-Morpholinol TPMT, MTAP, METTL3 SLC6A2 327/4885SLC6A3 158/4885CHRNA1 2248/4885
US-20090012328-A1 Process for preparing bupropion hydrochloride DBH, CBR3, CYP3A5 SLC6A2 132/4885SLC6A3 96/4885CHRNA1 208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.